Roivant Sciences ROIV Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Roivant Sciences in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Roivant Sciences’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Roivant Sciences's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Roivant Sciences's cash & equivalents?
- Roivant Sciences (ROIV) reported cash & equivalents of $1.42B in Q1 2026.
- How has Roivant Sciences's cash & equivalents changed year-over-year?
- Roivant Sciences's cash & equivalents increased by 1410.6% year-over-year, from $93.95M to $1.42B.
- What is the long-term trend for Roivant Sciences's cash & equivalents?
- Over 5 years (2020 to 2025), Roivant Sciences's cash & equivalents has grown at a -7.9% compound annual growth rate (CAGR), from $2.14B to $1.42B.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.